Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580649 | 0.79 | NPC1 (0.49) | F10PTGS2ALDH1A1 | |
| SCHEMBL29842516 | 0.75 | F10 (0.43) | F10PTGS2MEN1KMT2A | |
| SCHEMBL4903474 | 0.75 | PTGS2 (0.48) | F10PTGS2ALDH1A1 | |
| SCHEMBL28471494 | 0.73 | F10 (0.43) | F10PTGS2MEN1KMT2A | |
| SCHEMBL28755567 | 0.69 | CNR1 (0.49) | F10PTGS2ALDH1A1MEN1KMT2A | |
| SCHEMBL23064554 | 0.69 | HCAR1 (0.40) | F10PTGS2ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL21805487 | 0.69 | PIK3CD (0.40) | F10PTGS2ALDH1A1MEN1KMT2A | |
| SCHEMBL198132 | 0.68 | PTGS2 (0.57) | F10PTGS2MEN1KMT2A | |
| SCHEMBL1628707 | 0.68 | MAPT (0.47) | PTGS2ALDH1A1SMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL21805800 | 0.68 | PIK3CD (0.38) | F10PTGS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | CYP11B2, CYP3A43, CYP11B1 | F10 2414/4885PTGS2 2008/4885ALDH1A1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.